7 ms·
The point of single payer is to tell doctors and patients unambiguously how much they can spend. The free market puts the insurer(s), the provider(s), and the
by ineptech 2y ago
The point of single payer is to tell doctors and patients unambiguously how much they can spend. The free market puts the insurer(s), the provider(s), and the patient in a competition to see who can stick whom with the bill. The savings come more from not doing that than from the insurer's profit margin.
- mgraczyk 2y agoNHS currently does not recommend the treatment that this guy was receiving (as far as I could find): https://eastkentformulary.nhs.uk/media/1868/pr-2022-25-dual-biological-therapy-for-inflammatory-bowel-disease-ibd-in-adults.pdf https://eastkentformulary.nhs.uk/media/1868/pr-2022-25-dual-...
- alp1n3_eth 2y agoThe report you linked was from a single healthcare organization in the UK, not the entire NHS. Also, it mainly only covers their own cases and requests, they only treated 7,000 IBD patients in the specified year. It does state that there was a request received, and it would fund it. Dual biologics usually isn't considered until all the regular biologics have been tried by themselves. You don't seem to understand that biologics and surgery are literally the only things to combat this disease, and surgery can end up just being a bandaid: "The only formulary identified with a policy on dual biological therapy for IBD was South-East London which fund dual biologic therapy for severe, refractory CD in certain circumstances."